150-39-0Relevant articles and documents
Imaging of Enzyme Activity
-
, (2008/06/13)
This invention relates to biochemistry and magnetic resonance imaging.
Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
-
, (2008/06/13)
The invention relates to transport molecule binding ligand compounds which comprise a therapeutically and/or diagnostically active substance and a carrier molecule-affine substance with a high association constant to the carrier molecule. The invention also relates to medicaments containing these ligand compounds and to diagnostic kits.
Polypeptide derivatives
-
, (2008/06/13)
A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.
Iron chelate solutions
-
, (2008/06/13)
A method for the preparation of an aqueous solution of iron polyprotic acid chelate complexes, comprising reacting a solution of a mixture of a first polyprotic acid or a salt thereof, said first acid being capable of chelating iron, and a second polyprotic acid or a salt thereof, said second acid being capable of chelating iron and being different from the first acid, with iron in the presence of an oxidizing agent, with the proviso that at least part of the carboxylic acid groups in the first and second acids is present in salt form and at least part of the carboxylic acid groups in the first and second acids is present in acid form. Preferably, the first and second polyprotic acids may be selected from ethylenediaminetetraacetic acid (EDTA), N-hydroxyethyl-ethylenediaminetriacetic acid (HEDTA), and diethylenetriaminepentaacetic acid (DTPA), and the iron is selected from Fe-powder, Fe(OH)2 and FeCO3. Part of the polyprotic acid groups in the first and second acids is present in the salt form, the salt being selected from ammonium and alkali metal ions, in particular K , Na and mixtures thereof. The method makes it possible to obtain aqueous solutions containing high contents of iron, such as up to approximately 7% by weight of iron, for use as a plant nutrient, mainly in soil-free plant culturing.
Manganese (II) chelate manufacture
-
, (2008/06/13)
The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20° to 50° C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA. The Mn(II) chelate precipitates and low osmolarity solutions formed by the above processes are also aspects of this invention.